iShares Evolved U.S. Innovative Healthcare ETF
IEIH
Chicago Board Options Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- United States of America
- IPO Date
- Mar 21, 2018
- CIK
- 0001524513
- Similar Companies
- Business
- iShares Evolved U.S. Innovative Healthcare ETF (IEIH) is an exchange-traded fund that seeks to track the performance of an index composed of U.S. equities exhibiting innovative characteristics within the healthcare sector, including pharmaceuticals, biotechnology, and life sciences; it invests in growth and value stocks across diversified market capitalizations using quantitative analysis and proprietary research from BlackRock Fund Advisors. The fund benchmarks against the S&P Total Market Index and targets companies generating significant revenues from healthcare innovation, with top holdings historically including Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Merck & Co., Inc., and Bristol-Myers Squibb. Launched on March 21, 2018 by BlackRock, Inc. under the iShares U.S. ETF Trust and domiciled in the United States, it was managed from BlackRock Fund Advisors' offices at 400 Howard Street, San Francisco, California. The ETF provided exposure to U.S. public equity markets focused on healthcare innovation, serving investors seeking targeted sector growth through a passively managed vehicle with low-cost access to innovative healthcare providers and developers. In a significant operational change, BlackRock announced the termination and liquidation of the IEIH on June 17, 2022; trading ceased after market close on August 22, 2022, with proceeds distributed to shareholders on August 25, 2022, at $34.129785 per share, marking the fund's closure due to ongoing portfolio reviews and client feedback. No subsequent relaunches, partnerships, acquisitions, or strategic expansions have been reported for IEIH, which remains delisted and inactive. The fund operated solely in U.S. markets prior to liquidation, with no international geographic expansions or subsidiary relationships noted.